You are here

Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

Last updated on March 15, 2019

FOR MORE INFORMATION
Study Location
University of Alabama at Birmingham
Birmingham, Alabama, 35233 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Non-Small Cell Lung Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- histologically proven diagnosis of Non-Small Cell Lung Cancer (NSCLC) that is locally
advanced or metastatic and of the adenocarcinoma subtype (including mixed
adenosquamous histology)

- evident disease progression by Response Evaluation Criterion in Solid Tumors (RECIST)
after at least one but no more than 2 chemotherapy regimens for advanced disease

- tumors must have measurable disease as per RECIST

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- known interstitial lung disease

- prior treatment with an agent that is known or proposed to be active by action on EGFR
tyrosine kinase or c-Met/HGF (Phase 2 Portion)

NCT00965731
Pfizer
Completed
Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Non-Small Cell Lung Cancer ALK-positive, Non-Small Cell Lung Cancer c-Met Dependent, Non-Small Cell Lung Cancer ROS Marker Positive, Systemic Anaplastic Large-Cell Lymphoma, Advanced Malignancies Except Leukemia
NCT00585195
All Genders
18+
Years
Multiple Sites
Pancreatic Cancer, Non-Small Cell Lung Cancer, Cancer
NCT03637491
All Genders
18+
Years
Multiple Sites
Non-small Cell Lung Cancer
NCT01597258
All Genders
Non-Small Cell Lung Cancer
NCT00965731
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now